Clinical Study
AC-CUTE: An Open-Label Study to Evaluate Progression of Structural Joint Damage and Inflammation in Subjects with Moderate to Severe Rheumatoid Arthritis
Table 2
Changes in TSS and components and RAMRIS feature scores from baseline to Week 24.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
rank-sum test of the hypothesis of no change from baseline at Week 24. Testing change in each subgroup separately; FAS, full analysis set; TSS, Genant-modified total Sharp Score; SC-TCZC, subcutaneous tocilizumab combination therapy subgroup (including MTX); SC-TCZM, subcutaneous tocilizumab monotherapy subgroup (including DMARD(s) but excluding MTX). |